| abstract |
Certain new phenone derivatives of the formula (I) <IMAGE> in which R1=CH3, R2=H, Cl, Br, I, methyl, hydroxy, methoxy, propoxy, propoxy or ethoxy; R3=H or beta -D-glykosyl; R4=H, Cl, Br, I, methyl, hydroxy, methoxy, propoxy, iso-propoxy or ethoxy; R5=H or hydroxy, and the pharmaceutically acceptable salts, ethers and esters thereof, with the exception of the compounds 4-hydroxyacetophenone, 4-hydroxy-3-methoxy-acetophenone, 4-glucopyranosyloxy-acetophenone, 4-glucopyranosyloxy-3-methoxyacetophenone, 4-galactopyranosyloxy-3-methoxy-acetophenone, 4-glucopyranosyloxy-3,5-dimethoxy-acetophenone and galactopyranosyloxy-3,5-dimethoxy-acetophenone and a method for manufacturing them and pharmaceutical preparations containing them. The invention also concerns pharmaceutical preparations containing at least one compound of the formula (II) <IMAGE> in which R1 denotes H, OH, alkoxy or C1-8 alkyl; R2 denotes H or C1-4 alkoxy; R3 denotes OH or a beta -D/alpha-L-glykosyl group (di-or- triglykosyl) which is substituted optionally by low molecular C1-4 aliphatic or aromatic acids, R4 denotes H or C1-3 alkyl or C1-4 alkoxy; R5 denotes H, Cl, Br or I, R being, when it denotes halogen, in ortho position to a OH group, and the pharmaceutically acceptable salts, ethers and esters thereof together with pharmaceutically acceptable carriers and diluents. The new compounds including the compounds already known, have an antiphlogistic action. In vivo they inhibit in particular allergen- and PAF-induced bronchial asthma. |